Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063199 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29349956 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29384797 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31714182 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29358863 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL119588 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31369598 | 0.97 | MDM2 (0.53) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516252 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516240 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516235 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107163105-B | Crystallization method of natural linaclotide | 清华大学 | 2020-12-11 | — | — | CN | claimed |
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-22 | — | — | US | disclosed |
| US-20230406879-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-21 | — | — | US | disclosed |
| US-20230365643-A1 | PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11787836-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787836-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-10-17 | — | — | US | disclosed |
| CN-116457365-A | Peptides and cosmetic and pharmaceutical compositions comprising said peptides | 首尔大学医院 | 2023-07-18 | — | — | CN | disclosed |
| EP-4209500-A1 | PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Seoul National University Hospital (KR) | 2023-07-12 | — | — | EP | disclosed |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-1487493-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | The Administrators of The Tulane Educational Fund (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1435826-A2 | DIAGNOSTIC OR THERAPEUTIC SOMATOSTATIN OR BOMBESIN ANALOG CONJUGATES AND USES THEREOF | The Administrators of The Tulane Educational Fund (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003074551-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003028527-A2 | DIAGNOSTIC OR THERAPEUTIC SOMATOSTATIN OR BOMBESIN ANALOG CONJUGATES AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2003-04-10 | — | — | WO | disclosed |
| US-5776897-A | Treating disorders by application of insulin-like growth factors and analogs | CEPHALON, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5703045-A | NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5652214-A | ENHANCING SURVIVAL OF NEURONAL CELLS IN HEAD AND SPINAL CORD AFTER INJURY, ALSO TREATMENT OF AGING, ALZHEIMER*S, STROKE, EPILEPSY | CEPHALON, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0604605-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885MDM2 3845/4885 |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885MDM2 3845/4885 |
| US-20230406879-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885MDM2 3845/4885 |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885MDM2 3845/4885 |
| US-11787836-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885MDM2 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.